Has Amit Rout received payments from drug or device companies?

Yes. Drug and device makers reported $7,821 in general payments to Amit Rout across 128 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Amit Rout did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Amit Rout come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Amit Rout

Cardiovascular Disease · Louisville, KYNPI 1104349315

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,915 of the $7,821 with a category attached, or 62.8%. 18 manufacturers reported payments, led by Boston Scientific at 34.5% of the total.

$7,821in general payments, 2019–2025

Across 128 payments — averaging $61.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$3K
Edwards Lifesciences$2K
Medtronic$794
Abbott$640
Terumo Medical Corporation$566
Novartis$295
plus $1K from 12 others

What the payments were for

Travel & lodging$2,68434%
Food & beverage$4,91563%
Education$2223%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	37	$2,699
Edwards Lifesciences	13	$1,569
Medtronic	12	$794
Abbott	15	$640
Terumo Medical Corporation	6	$566
Novartis	9	$295
Chiesi USA, Inc.	5	$237
Pfizer	9	$200
Amgen	5	$191
Philips North America LLC	3	$187
Penumbra, Inc.	1	$107
Stryker	3	$88
AstraZeneca	4	$67
Abiomed	1	$46
E.r. Squibb & Sons, L.L.C.	2	$42
Inari Medical, Inc.	1	$41
Actelion Pharmaceuticals US, Inc.	1	$38
Esperion Therapeutics, Inc.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,821 in reported general payments places this provider in the 80th percentile of 258 cardiovascular disease providers in Kentucky.

See all cardiovascular disease providers in Kentucky →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Metoprolol Succinate	14	$151
Atorvastatin Calcium	12	$60
Furosemide	13	$25

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Louisville

Amir PirachaLouisville$530K
Dinesh KalraLouisville$316K
John HarrisLouisville$129K
Rohan SamsonLouisville$94K
Vipul PanchalLouisville$39K
Steven RaibleLouisville$30K
Chandhiran RangaswamyLouisville$19K
Joseph LashLouisville$16K
Shanker ChandiramaniLouisville$16K
Pradeep SinghLouisville$15K

See the full list for Kentucky →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →